Business Context and Reporting Period
This Form 8-K reports on events occurring on December 6, 2016, regarding DanDrit Biotech USA, Inc. (a Delaware corporation). The filing details the results of a special meeting of stockholders held to approve corporate restructuring measures, including a name change and a reverse stock split. The record date for the meeting was October 31, 2016.
Key Financial Metrics
This filing is a current report regarding corporate governance and structural changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
- Name Change: Stockholders approved amending the Certificate of Incorporation to change the company name from "DanDrit Biotech USA, Inc." to "OncoSynergy, Inc."
- Reverse Stock Split: Stockholders approved a 1-for-2.3 reverse stock split of issued and outstanding common stock. The effective date is to be determined by the Board of Directors.
- Board Elections: Dr. Eric Leire, N.E. Nielsen, and Aldo Petersen were elected as directors.
- Accounting Firm: Gregory & Associates, LLC was ratified as the independent registered accounting firm.
Voting Results and Management Commentary
A total of 7,768,394 shares were present or represented by proxy, representing approximately 81% of the outstanding common stock. All five proposals submitted were approved with overwhelming support:
- Proposal 1 (Directors): All three nominees received 7,230,718 votes "For" and 500,058 votes "Withheld".
- Proposal 2 (Name Change): 7,230,698 votes "For" vs. 20 votes "Against".
- Proposal 3 (Reverse Split): 7,230,698 votes "For" vs. 78 votes "Against".
- Proposal 4 (Auditor Ratification): 7,268,306 votes "For" vs. 0 votes "Against".
- Proposal 5 (Adjournment): 7,268,364 votes "For" vs. 0 votes "Against".
The filing does not contain specific management commentary on future outlook, risks, or contingencies beyond the procedural details of the vote.
Investor Verification Checklist
- Verify the effective date of the 1-for-2.3 reverse stock split as determined by the Board of Directors.
- Confirm the ticker symbol change associated with the name change to "OncoSynergy, Inc."
- Review the Proxy Statement filed on November 21, 2016, for the full text of the Certificate of Amendment.
- Monitor subsequent filings for the updated share count post-split.